troglitazone has been researched along with Heart Failure in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These hemodynamic changes suggest that a single oral dose of troglitazone induced inotropy without activation of the sympathetic nervous system." | 6.70 | Troglitazone improves cardiac function in patients with congestive heart failure. ( Endo, A; Furuse, Y; Hisatome, I; Igawa, O; Ikawa, S; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Uchida, K, 2002) |
| "These hemodynamic changes suggest that a single oral dose of troglitazone induced inotropy without activation of the sympathetic nervous system." | 2.70 | Troglitazone improves cardiac function in patients with congestive heart failure. ( Endo, A; Furuse, Y; Hisatome, I; Igawa, O; Ikawa, S; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Uchida, K, 2002) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "To determine, in patients with type 2 diabetes mellitus, whether an association exists between thiazolidinedione therapy or other diabetes therapies and hospital admission for heart failure." | 1.33 | Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. ( Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogino, K | 1 |
| Furuse, Y | 1 |
| Uchida, K | 1 |
| Shimoyama, M | 1 |
| Kinugawa, T | 1 |
| Osaki, S | 1 |
| Kato, M | 1 |
| Endo, A | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Ikawa, S | 1 |
| Shigemasa, C | 1 |
| Hartung, DM | 1 |
| Touchette, DR | 1 |
| Bultemeier, NC | 1 |
| Haxby, DG | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
1 review available for troglitazone and Heart Failure
| Article | Year |
|---|---|
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
1 trial available for troglitazone and Heart Failure
| Article | Year |
|---|---|
Troglitazone improves cardiac function in patients with congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Catecholamines; Chromans; Cross-Over Studies; Diabetes Mellitus, Typ | 2002 |
1 other study available for troglitazone and Heart Failure
| Article | Year |
|---|---|
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospi | 2005 |